We are live on ! Find out more
PHVS icon

Pharvaris
PHVS

51 hedge funds and large institutions have $834M invested in Pharvaris in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 3

133% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 6

42% more funds holding

Funds holding: 36 → 51 (+15)

3.49% more ownership

Funds ownership: 79.91% → 83.4% (+3.5%)

3% more capital invested

Capital invested by funds: $809M → $834M (+$25.7M)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
51
Holders Change
+15
Holders Change %
+41.67%
% of All Funds
0.73%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
18
Increased
14
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$11.6M
2
OCA
Octagon Capital Advisors
New York
+$11.3M
3
PSC
Patient Square Capital
California
+$4.43M
4
SCM
Soleus Capital Management
Connecticut
+$3.63M
5
BlackRock
BlackRock
New York
+$3.53M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$4.75M
2
Walleye Capital
Walleye Capital
New York
-$917K
3
TD Asset Management
TD Asset Management
Ontario, Canada
-$906K
4
YIH
Y-Intercept (HK)
Hong Kong
-$299K
5
Citadel Advisors
Citadel Advisors
Florida
-$272K
Name Holding Trade Value Shares
Change 		Change in
Stake
GA
1
General Atlantic
New York
$139M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$96.4M – – –
FCMI
3
Foresite Capital Management IV
California
$81.4M +$1.9M +104,027 +2%
VP
4
venBio Partners
California
$79.4M – – –
Viking Global Investors
5
Viking Global Investors
Connecticut
$67.7M – – –
VA
6
VR Adviser
New York
$62.9M – – –
BCLSI
7
Bain Capital Life Sciences Investors
Massachusetts
$61.2M – – –
DM
8
Deerfield Management
New York
$37.6M +$11.6M +634,421 +45%
CC
9
Commodore Capital
New York
$35.4M +$1.85M +101,258 +6%
NHAS
10
Novo Holdings A/S
Denmark
$31.9M – – –
CAM
11
Cormorant Asset Management
Massachusetts
$27.2M – – –
EC
12
EcoR1 Capital
California
$16.7M – – –
5VM
13
5AM Venture Management
California
$14.8M – – –
RSCM
14
Rock Springs Capital Management
Maryland
$14M – – –
OCA
15
Octagon Capital Advisors
New York
$11.5M +$11.3M +620,470 New
SI
16
Sofinnova Investments
California
$11.1M -$22.5K -1,232 -0.2%
SCM
17
Soleus Capital Management
Connecticut
$11.1M +$3.63M +198,739 +50%
SFM
18
Sphera Funds Management
Israel
$8.14M +$658K +36,027 +9%
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$6.03M -$4.75M -259,783 -44%
PSC
20
Patient Square Capital
California
$4.49M +$4.43M +242,341 New
BlackRock
21
BlackRock
New York
$3.62M +$3.53M +193,080 +8,513%
Goldman Sachs
22
Goldman Sachs
New York
$1.18M +$43.1K +2,360 +4%
Marshall Wace
23
Marshall Wace
United Kingdom
$1.09M +$143K +7,846 +15%
State Street
24
State Street
Massachusetts
$1,000K +$986K +53,980 New
UBS AM
25
UBS AM
Illinois
$906K +$893K +48,896 New
1
2 3

PHVS Hedge Fund Activity: Q3 2024 in Review

51 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in Pharvaris (PHVS) for Q3 2024, worth a combined $834M — up 3.2% from $809M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new PHVS positions and 3 closed out — a net gain of 15 holders — while 14 added to existing stakes and 6 trimmed.

The largest buyer was Deerfield Management, adding an estimated $11.6M. The largest seller was T. Rowe Price Associates, cutting an estimated $4.75M.

  • 51 institutional investors held Pharvaris (PHVS) as of Q3 2024, up from 36 in Q2 2024.
  • Funds reported $834M of Pharvaris stock for Q3 2024, up 3.2% quarter-over-quarter.
  • 18 funds opened new Pharvaris positions in Q3 2024 and 3 closed out, a net change of +15 holders.
  • The largest Pharvaris buyer in Q3 2024 was Deerfield Management, an estimated $11.6M added.
  • The largest Pharvaris seller in Q3 2024 was T. Rowe Price Associates, an estimated $4.75M sold.

Based on aggregated 13F filings for Q3 2024.